60 degrees pharmaceuticals awarded canadian patent covering tafenoquine for prevention of malaria in malaria-naive subjects

Washington, july 31, 2023 (globe newswire) -- 60 degrees pharmaceuticals inc. (“60p” or the “company”) (nasdaq: sxtp), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the canadian intellectual property office (cipo) has issued the company a patent covering the use of novel regimens of tafenoquine for the prevention of malaria in malaria-naive individuals. travelers from, and residents of, canada and the united states, are usually malaria naÏve because they have not previously contracted malaria and thus lack immunity to the disease.
SXTP Ratings Summary
SXTP Quant Ranking